Neurocrine Biosciences has announced the initiation of a phase I first-in-human clinical trial to evaluate NBIP-2118, an investigational corticotropin-releasing factor type 2 (CRF2) receptor peptide agonist being developed as a potential first-in-class treatment for obesity. The study will assess the safety and tolerability of single ascending doses of the drug in healthy-weight adults as well as individuals who are overweight or obese, with initial results anticipated in 2027.

NBIP-2118 is designed for once-weekly subcutaneous administration and has demonstrated promising results in preclinical models. The therapy showed high selectivity and potency, with weight loss primarily driven by fat reduction while preserving or even increasing lean muscle mass. This differentiated mechanism could address a key limitation of existing obesity treatments, which often lead to significant lean mass loss.

According to Neurocrine, targeting CRF2 receptors offers a novel therapeutic approach that could be used both as a standalone treatment and in combination with other therapies, including incretin-based drugs. The company is also advancing a broader obesity pipeline, including NBIP-1968, a triple agonist targeting GLP-1, GIP and glucagon receptors, as well as other combination and long-acting treatment approaches aimed at improving efficacy and dosing convenience.

Obesity remains a major global health challenge, associated with conditions such as type 2 diabetes, cardiovascular disease and certain cancers. Despite recent advances, there is still a need for therapies that deliver sustainable weight loss while maintaining overall health and muscle mass.

With this clinical milestone, Neurocrine aims to expand its footprint beyond neurological and endocrine disorders into metabolic disease, leveraging its expertise in CRF biology to develop innovative and differentiated treatment options.